160 related articles for article (PubMed ID: 17943722)
21. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
22. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.
Fristrup N; Birkenkamp-Demtröder K; Reinert T; Sanchez-Carbayo M; Segersten U; Malmström PU; Palou J; Alvarez-Múgica M; Pan CC; Ulhøi BP; Borre M; Ørntoft TF; Dyrskjøt L
Am J Pathol; 2013 Feb; 182(2):339-49. PubMed ID: 23201130
[TBL] [Abstract][Full Text] [Related]
23. [EZH2 expression in human prostate cancer and its clinicopathologic significance].
Li J; Fan QH; Fan XS; Zhou W; Qiu Y; Qiu L
Zhonghua Nan Ke Xue; 2010 Feb; 16(2):123-8. PubMed ID: 20369694
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
[TBL] [Abstract][Full Text] [Related]
25. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.
Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
Anticancer Res; 2006; 26(6C):4873-8. PubMed ID: 17214354
[TBL] [Abstract][Full Text] [Related]
26. Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication.
Fujioka S; Shomori K; Nishihara K; Yamaga K; Nosaka K; Araki K; Haruki T; Taniguchi Y; Nakamura H; Ito H
Lung Cancer; 2009 Aug; 65(2):223-9. PubMed ID: 19144445
[TBL] [Abstract][Full Text] [Related]
27. Ki-67 and minichromosome maintenance-7 (MCM7) expression in canine pituitary corticotroph adenomas.
Ishino H; Hara Y; Takekoshi S; Teshima T; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2011 Nov; 41(4):207-13. PubMed ID: 21982272
[TBL] [Abstract][Full Text] [Related]
28. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer.
Padmanabhan V; Callas P; Philips G; Trainer TD; Beatty BG
J Clin Pathol; 2004 Oct; 57(10):1057-62. PubMed ID: 15452160
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens.
Rubio J; Ramos D; López-Guerrero JA; Iborra I; Collado A; Solsona E; Almenar S; Llombart-Bosch A
Eur Urol; 2005 Nov; 48(5):745-51. PubMed ID: 16139948
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.
Vis AN; Noordzij MA; Fitoz K; Wildhagen MF; Schröder FH; van der Kwast TH
J Urol; 2000 Dec; 164(6):2156-61. PubMed ID: 11061947
[TBL] [Abstract][Full Text] [Related]
31. [Prognostic factors of prostate cancer: usefulness of Ki-67 expression in preoperative biopsies].
Ojea Calvo A; Mosteiro Cerviño MJ; Domínguez Freire F; Alonso Rodrigo A; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; González Piñeiro A
Arch Esp Urol; 2004 Oct; 57(8):805-16. PubMed ID: 15560269
[TBL] [Abstract][Full Text] [Related]
32. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.
Karnes RJ; Cheville JC; Ida CM; Sebo TJ; Nair AA; Tang H; Munz JM; Kosari F; Vasmatzis G
Cancer Res; 2010 Nov; 70(22):8994-9002. PubMed ID: 21062978
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer.
Yang J; Ramnath N; Moysich KB; Asch HL; Swede H; Alrawi SJ; Huberman J; Geradts J; Brooks JS; Tan D
BMC Cancer; 2006 Aug; 6():203. PubMed ID: 16882345
[TBL] [Abstract][Full Text] [Related]
34. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
Choi JH; Song YS; Yoon JS; Song KW; Lee YY
APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
[TBL] [Abstract][Full Text] [Related]
35. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67.
Taftachi R; Ayhan A; Ekici S; Ergen A; Ozen H
BJU Int; 2005 Mar; 95(4):650-4. PubMed ID: 15705097
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.
Ekici S; Cerwinka WH; Duncan R; Gomez P; Civantos F; Soloway MS; Lokeshwar VB
Int J Cancer; 2004 Oct; 112(1):121-9. PubMed ID: 15305383
[TBL] [Abstract][Full Text] [Related]
37. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.
Jacobs C; Tumati V; Kapur P; Yan J; Hong D; Bhuiyan M; Xie XJ; Pistenmaa D; Yu L; Hsieh JT; Saha D; Kim DW
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):729-35. PubMed ID: 24867541
[TBL] [Abstract][Full Text] [Related]
38. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort.
Richardsen E; Andersen S; Al-Saad S; Rakaee M; Nordby Y; Pedersen MI; Ness N; Grindstad T; Movik I; Dønnem T; Bremnes R; Busund LT
PLoS One; 2017; 12(11):e0186852. PubMed ID: 29141018
[TBL] [Abstract][Full Text] [Related]
40. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy.
Bubendorf L; Sauter G; Moch H; Schmid HP; Gasser TC; Jordan P; Mihatsch MJ
J Pathol; 1996 Apr; 178(4):437-41. PubMed ID: 8691323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
